Phase
Condition
Hemorrhage
Female Hormonal Deficiencies/abnormalities
Menstrual Disorders
Treatment
Placebo
Curcumin
Clinical Study ID
Ages 15-45 Female Accepts Healthy Volunteers
Study Summary
Eligibility Criteria
Inclusion
Inclusion Criteria:
English speaking
Women 15-45 years of age
Currently using the ENG implant for at least 30 days and use proven on exam (palpation of implant at screening visit)
Willing to continue using the implant for at least 30 days from study enrollment
>7 days of continuous bleeding/spotting in the last 30 days, OR 2 or more episodesof bleeding/spotting in the last 30 days.
Access to a reliable cell phone and must be willing to receive and respond to adaily text or email message to assess bleeding and use of study drug
Negative gonorrhea/chlamydia screening performed at screening visit
Exclusion
Exclusion Criteria:
Postpartum within six months
Post-abortion within six weeks
Currently pregnant
Currently breast-feeding (to be eligible, must be 4-6 weeks from cessation ofbreastfeeding)
Undiagnosed abnormal uterine bleeding pre-dating placement of contraceptive implant
Bleeding dyscrasia
Anticoagulation use
Active cervicitis
Allergy to curcumin or turmeric
History of venous thromboembolism
Current or past breast or uterine malignancy
Use of P450 pathway inducing drug
Implant is due to be switched out in 2 months or less from enrollment
Currently using oral contraceptives in addition to implant (to be eligible, needs tohave a 4-6 week washout period)
Prior pregnancy occurred while Nexplanon/Implanon was in place
Study Design
Study Description
Connect with a study center
OHSU
Portland, Oregon 97239
United StatesSite Not Available
Not the study for you?
Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.